TORONTO — NetraMark Holdings Inc. has announced its participation in the upcoming H.C. Wainwright 28th Annual Global Investment Conference, where it will present its cutting-edge clinical intelligence solutions to institutional investors.
The company, recognized for utilizing AI-powered precision analytics to transform drug discovery and clinical trial outcomes, will premiere a virtual corporate presentation on September 11. Following the broadcast, executive leadership will conduct in-person meetings in New York City on September 14 and 15.
The summit offers NetraMark a prominent stage to highlight how its proprietary technology mitigates trial failure risks.